Advertisement
ALGN vs DXCM
Which Stock Would AI Choose? Align Technology (ALGN) vs. DexCom (DXCM) Stock Comparison
Key Takeaways
- ALGN has delivered stronger year-to-date (YTD) gains of about 18%, outpacing DXCM's roughly 7% rise amid recent market activity.
- DXCM boasts a larger market capitalization (market cap) at approximately $24 billion versus ALGN's $13 billion, reflecting greater scale in the medical device sector.
- Both stocks anticipate solid revenue growth in upcoming quarterly results, with ALGN projecting year-over-year increases and DXCM around 14%.
- Analyst price targets indicate potential upside: 12% for ALGN to about $207 and over 40% for DXCM to $87, signaling optimism for both.
- ALGN trades near the middle of its 52-week range ($122-$208), while DXCM hovers closer to its low ($54-$90), highlighting relative momentum differences.
Introduction
Align Technology (ALGN) and DexCom (DXCM) represent innovative players in the medical technology space, with ALGN leading in clear aligner orthodontics and DXCM advancing continuous glucose monitoring (CGM) for diabetes management. This stock comparison examines their recent performance, growth drivers, and market positioning amid evolving healthcare demands. Growth-oriented investors and traders tracking medtech trends may find value in understanding their relative strengths, as both navigate macroeconomic pressures and sector-specific catalysts like product adoption and earnings outlooks. By highlighting contrasts in momentum and fundamentals, this analysis aids informed decision-making in a competitive landscape.
ALGN Overview and Recent Performance
Align Technology (ALGN), headquartered in Tempe, Arizona, specializes in Invisalign clear aligners, retainers, and iTero intraoral scanners through its Clear Aligner and Imaging Systems segments. The company serves orthodontic needs globally, benefiting from rising demand for aesthetic dental solutions. In recent market activity, ALGN shares have rebounded, trading around $185-$190 within a 52-week range of $122 to $208, supported by year-to-date gains near 18%. Sentiment has improved with recognition as a LexisNexis Top 100 Global Innovator for the fifth year and anticipation for Q1 results projecting $1.02 billion in revenue and EPS growth. Analyst targets average $207, with recent upgrades like Morgan Stanley's raise to $188, reflecting confidence in volume recovery and international expansion despite broader economic headwinds.
DXCM Overview and Recent Performance
DexCom (DXCM), based in San Diego, California, develops CGM systems like Dexcom G7 and G6 for diabetes and metabolic health management, targeting physicians and patients worldwide. Its focus on real-time glucose tracking has driven adoption amid rising diabetes prevalence. Recently, DXCM shares have faced pressure, trading near $61 in a 52-week range of $54 to $90, with modest YTD gains around 7% but softer one-month performance. Key influences include share weakness over longer periods, offset by strong G7 uptake expectations and projected 13.6% Q1 revenue growth ahead of April 30 earnings. Analysts maintain a positive outlook with an average target of $87, including Citigroup's Buy rating and target hike to $84, buoyed by product launches and resilience against weight-loss drug competition.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing bots curated from a library of 351 AI trading bots that analyze and trade thousands of tickers across stocks, ETFs, and crypto. These bots stand out for their suitability to current market conditions, featuring diverse strategies like technical and fundamental analysis, with risk levels from low to high volatility tolerance. Performance metrics such as win rates, return on investment (ROI), and timeframes (e.g., 5-minute to 60-minute intervals) are prominently displayed, alongside real-time signals for copy trading via AI Trading Signal Agents, Virtual Agents with customizable risk management, and Brokerage Agents. Plans range from Intermediate to Expert levels. Traders can explore these high-potential options to enhance strategies—visit the Trending AI Robots page for details tailored to today's environment.
Head-to-Head Comparison
ALGN and DXCM both operate in healthcare medtech but diverge in focus: ALGN's orthodontic aligners tap elective procedures with recurring scanner sales, while DXCM's CGM devices address chronic diabetes needs with subscription-like sensor replacements. Growth drivers include ALGN's international Invisalign volumes and DXCM's G7 sensor expansions, both projecting double-digit revenue trajectories. Recent momentum favors ALGN with superior YTD returns and price stability versus DXCM's near-term dips. Risk factors contrast too—ALGN faces consumer spending sensitivity, DXCM contends with GLP-1 drug competition—while DXCM's larger market cap offers scale advantages. Market sentiment leans positive for both per analyst targets, though ALGN exhibits tighter price-to-earnings (P/E) forward multiples around 16 versus DXCM's ongoing CGM leadership.
Tickeron AI Verdict
Tickeron's AI currently leans toward ALGN based on its consistent recent trend strength, superior YTD momentum, and favorable positioning ahead of growth-oriented earnings. DXCM shows recovery potential via higher upside targets and product catalysts, but ALGN's relative stability and rebound dynamics present a probabilistic edge in the near term for trend-following models.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Hold and DXCM is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 0 FA rating(s) are green whileDXCM’s FA Score has 1 green FA rating(s).
- ALGN’s FA Score: 0 green, 5 red.
- DXCM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 4 TA indicator(s) are bullish while DXCM’s TA Score has 6 bullish TA indicator(s).
- ALGN’s TA Score: 4 bullish, 6 bearish.
- DXCM’s TA Score: 6 bullish, 4 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а +1.92% price change this week, while DXCM (@Medical/Nursing Services) price change was +2.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.72%. For the same industry, the average monthly price growth was +1.78%, and the average quarterly price growth was -13.43%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.24%. For the same industry, the average monthly price growth was -0.16%, and the average quarterly price growth was -16.01%.
Reported Earning Dates
ALGN is expected to report earnings on Jul 29, 2026.
DXCM is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.72% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-0.24% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ALGN | DXCM | ALGN / DXCM | |
| Capitalization | 11.6B | 28.1B | 41% |
| EBITDA | 877M | 1.48B | 59% |
| Gain YTD | 3.561 | 9.643 | 37% |
| P/E Ratio | 27.18 | 31.23 | 87% |
| Revenue | 4.1B | 4.82B | 85% |
| Total Cash | 1.06B | 2.42B | 44% |
| Total Debt | 116M | 1.39B | 8% |
ALGN | DXCM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 27 | |
PRICE GROWTH RATING 1..100 | 59 | 44 | |
P/E GROWTH RATING 1..100 | 64 | 94 | |
SEASONALITY SCORE 1..100 | 25 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (69) in the Medical Specialties industry is in the same range as DXCM (75). This means that ALGN’s stock grew similarly to DXCM’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DXCM (100). This means that ALGN’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is somewhat better than the same rating for ALGN (69). This means that DXCM’s stock grew somewhat faster than ALGN’s over the last 12 months.
DXCM's Price Growth Rating (44) in the Medical Specialties industry is in the same range as ALGN (59). This means that DXCM’s stock grew similarly to ALGN’s over the last 12 months.
ALGN's P/E Growth Rating (64) in the Medical Specialties industry is in the same range as DXCM (94). This means that ALGN’s stock grew similarly to DXCM’s over the last 12 months.
| ALGN | DXCM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 69% | 2 days ago 70% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 71% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 69% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 72% |
| Advances ODDS (%) | 6 days ago 71% | 3 days ago 70% |
| Declines ODDS (%) | 2 days ago 74% | 8 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 67% |
Advertisement
ALGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALGN has been loosely correlated with BAX. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if ALGN jumps, then BAX could also see price increases.
| Ticker / NAME | Correlation To ALGN | 1D Price Change % | ||
|---|---|---|---|---|
| ALGN | 100% | -2.99% | ||
| BAX - ALGN | 63% Loosely correlated | -0.75% | ||
| NVST - ALGN | 56% Loosely correlated | -2.35% | ||
| LUNG - ALGN | 52% Loosely correlated | -5.59% | ||
| XRAY - ALGN | 50% Loosely correlated | -1.88% | ||
| ILMN - ALGN | 48% Loosely correlated | +5.16% | ||
More | ||||
DXCM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To DXCM | 1D Price Change % | ||
|---|---|---|---|---|
| DXCM | 100% | -0.93% | ||
| ISRG - DXCM | 46% Loosely correlated | +1.24% | ||
| ALGN - DXCM | 44% Loosely correlated | -2.99% | ||
| SYK - DXCM | 41% Loosely correlated | +0.58% | ||
| NVST - DXCM | 40% Loosely correlated | -2.35% | ||
| GKOS - DXCM | 39% Loosely correlated | +2.58% | ||
More | ||||